Medicinal Cannabis

TGA Updates for Medicinal Cannabis

The TGA recently held webinars about reforms that impact the medicinal cannabis industry, including:

Changes to prescribing medicinal cannabis through the Special Access Scheme (SAS) and Authorised Prescriber (AP) pathways
The removal of TGO 93 Standard for Medicinal Cannabis …

GMP Vendor Management Audit Program

Supplying Medicinal Cannabis in Australia

The TGA recently held a webinar called ‘Meeting Your Obligations – Supplying medicinal cannabis in Australia,’ and while it was useful as an overview of the therapeutic good development lifecycle, it did not delve too much into the main …

insurance-for-medicinal-cannabis-operations1

Medicinal Cannabis Stability

As the medical cannabis industry matures, a question has started popping up more frequently regarding medicinal cannabis stability, namely: “What do I put down for shelf life/expiry for a new medicinal cannabis product?”

In this blog we provide a brief …

TGA-Medicinal-Cannabis

TGA Medicinal Cannabis

I’m often asked to clarify the difference between TGA Medicinal Cannabis and EU GMP Medicinal Cannabis, i.e. who is that has the highest “Gold Standard” for Medicinal Cannabis? I suspect this has come about because many are trying to …

APVMA-GMP-Training-Australian-code-of-GMP-veterinary-chemical-products

S4 CBD for pets and livestock

Given the TGA’s strict supply pathways it would be easy to assume that medicinal cannabis is reserved solely for humans, however, this is not the case. In fact, veterinarians are also able to use certain cannabinoids to treat pets …

Young-doctor-offering-pill

Compliant Medicinal Cannabis Advertising

As many in the pharmaceutical industry know, the TGA has strict rules on advertising therapeutic goods. These rules are outlined via the Therapeutics Goods Advertising Code as well as guidance provided in Australian Regulatory Guidelines for Advertising Therapeutic Goods …

can-you-insure-cannabis-crops-insurance

The Future of CBD

Many heralded the TGA’s proposal to downschedule low-dose cannabidiol (CBD) to S3 as groundbreaking, however, as I’ve covered in a previous blog, there are additional complications that need to be addressed. The TGA’s initial safety review made recommendations for …